"Involvement of companies in international drug trafficking scheme are deeply troubling"

In a statement released by Tilray Brands following the recent raids on several MMJ companies by local law enforcement, the company said the following:

"As we navigate the evolving landscape of the medicinal cannabis industry, it is crucial to uphold the highest standards of integrity and transparency. The recent police operation in Portugal has highlighted significant breaches of trust and regulatory compliance within our sector. I commend the efforts of the Judicial Police in uncovering the alleged illicit activities that have unfortunately marred the reputation of medicinal cannabis.

The revelations that certain pharmaceutical companies authorized to produce and sell medicinal cannabis presumably have been involved in an international drug trafficking scheme are deeply troubling. The falsification of drug production licenses and the exploitation of regulatory vulnerabilities to divert medicinal cannabis to the black market undermine the legitimate efforts of countless professionals dedicated to ensuring the safe and ethical use of medicinal cannabis.

This incident serves as a stark reminder of the importance of rigorous oversight and strict adherence to legal frameworks. It is imperative that we, as industry leaders, work collaboratively with regulatory bodies like Infarmed and other national authorities to strengthen the inspection and control systems. By doing so, we can prevent violations and protect the integrity of our industry.

We must remain vigilant and proactive in our efforts to ensure that medicinal cannabis is used solely for its intended purpose – to provide therapeutic benefits to patients in need. I urge all stakeholders to join us in reaffirming our commitment to ethical practices and to support measures that enhance transparency and accountability within the medicinal cannabis sector.

I would like to express my deepest appreciation to the Judicial Police for their diligence and dedication in addressing this issue. Let us take this opportunity to reinforce our collective resolve to build a robust and trustworthy medicinal cannabis industry that prioritizes patient safety and public health."